HISTOGEN INC (HSTO) Stock Price & Overview
NASDAQ:HSTO • US43358Y2028
The current stock price of HSTO is 0.658 USD. Today HSTO is up by 29.27%. In the past month the price decreased by -1.2%. In the past year, price decreased by -55.54%.
HSTO Key Statistics
- Market Cap
- 2.81M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.92
- Dividend Yield
- N/A
HSTO Stock Performance
HSTO Stock Chart
HSTO Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to HSTO. When comparing the yearly performance of all stocks, HSTO is a bad performer in the overall market: 85.61% of all stocks are doing better.
HSTO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to HSTO. The financial health of HSTO is average, but there are quite some concerns on its profitability.
HSTO Earnings
HSTO Forecast & Estimates
7 analysts have analysed HSTO and the average price target is 2.04 USD. This implies a price increase of 210.03% is expected in the next year compared to the current price of 0.658.
For the next year, analysts expect an EPS growth of 26.45% and a revenue growth -99.88% for HSTO
HSTO Groups
Sector & Classification
HSTO Financial Highlights
Over the last trailing twelve months HSTO reported a non-GAAP Earnings per Share(EPS) of -2.92. The EPS increased by 41.01% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -89.51% | ||
| ROE | -130.43% | ||
| Debt/Equity | 0 |
HSTO Ownership
HSTO Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.26 | 413.319B | ||
| AMGN | AMGEN INC | 16.83 | 203.007B | ||
| GILD | GILEAD SCIENCES INC | 16.62 | 183.41B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.44 | 120.332B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.95 | 81.051B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.86 | 42.097B | ||
| INSM | INSMED INC | N/A | 31.351B | ||
| NTRA | NATERA INC | N/A | 29.344B | ||
| BIIB | BIOGEN INC | 12.48 | 27.007B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.41 | 21.856B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.914B | ||
| EXAS | EXACT SCIENCES CORP | 309.36 | 19.724B | ||
| MRNA | MODERNA INC | N/A | 19.468B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About HSTO
Company Profile
Histogen, Inc. engages in the development of potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function. The company is headquartered in San Diego, California and currently employs 7 full-time employees. The company went IPO on 2013-07-25. The firm is focused on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function. Its product candidates include emricasan, CTS-2090 and CTS-2096. The company develops emricasan for acute bacterial skin and skin structure infections (ABSSSI) as well evaluating its use for other infectious diseases. Its pipeline also includes novel preclinical product candidates including CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of certain inflammatory diseases. Emricasan is an orally available pan-caspase inhibitor designed to reduce the activities of human caspases, which are enzymes that mediate inflammation and apoptosis. CTS-2090 and CTS-2096 are selective caspase-1 inhibitors targeting inflammasome activation and to treat a variety of inflammation mediated diseases.
Company Info
HISTOGEN INC
10655 Sorrento Valley Road, Suite 200
San Diego CALIFORNIA 92121 US
CEO: Richard W. Pascoe
Employees: 7
Phone: 18585263100.0
HISTOGEN INC / HSTO FAQ
What does HISTOGEN INC do?
Histogen, Inc. engages in the development of potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function. The company is headquartered in San Diego, California and currently employs 7 full-time employees. The company went IPO on 2013-07-25. The firm is focused on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function. Its product candidates include emricasan, CTS-2090 and CTS-2096. The company develops emricasan for acute bacterial skin and skin structure infections (ABSSSI) as well evaluating its use for other infectious diseases. Its pipeline also includes novel preclinical product candidates including CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of certain inflammatory diseases. Emricasan is an orally available pan-caspase inhibitor designed to reduce the activities of human caspases, which are enzymes that mediate inflammation and apoptosis. CTS-2090 and CTS-2096 are selective caspase-1 inhibitors targeting inflammasome activation and to treat a variety of inflammation mediated diseases.
What is the stock price of HISTOGEN INC today?
The current stock price of HSTO is 0.658 USD. The price increased by 29.27% in the last trading session.
What is the dividend status of HISTOGEN INC?
HSTO does not pay a dividend.
How is the ChartMill rating for HISTOGEN INC?
HSTO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What do analysts say about HISTOGEN INC (HSTO) stock?
7 analysts have analysed HSTO and the average price target is 2.04 USD. This implies a price increase of 210.03% is expected in the next year compared to the current price of 0.658.
What is the GICS sector and industry of HSTO stock?
HISTOGEN INC (HSTO) operates in the Health Care sector and the Biotechnology industry.
When does HISTOGEN INC (HSTO) report earnings?
HISTOGEN INC (HSTO) will report earnings on 2023-11-08, after the market close.